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Substance use disorders are among themost common health problems of people involved with the criminal justice
system. Scaling up addiction services in prisons is a global public health and human rights challenge, especially in
poorly resourced countries. We systematically reviewed the prevalence of substance use in prison populations in
low- andmiddle-income countries.We searched for studies reporting prevalence rates of nicotine, alcohol, illicit drug,
and injection drug use during imprisonment in unselected samples of imprisoned people in low- and middle-income
countries. Data meta-analysis was conducted and sources of heterogeneity were examined by meta-regression.
Prevalence of nicotine use during imprisonment ranged from 5% to 87%, with a random-effects pooled estimate of
56% (95%conﬁdence interval (CI): 45, 66) with signiﬁcant geographical heterogeneity. Alcohol use varied from1% to
76% (pooled prevalence, 16%, 95% CI: 9, 25). Approximately one-quarter of people (25%; 95% CI: 17, 33; range,
0–78) used illicit drugs during imprisonment. The prevalence of injection drug use varied from0% to 26% (pooled esti-
mate, 1.6%, 95% CI: 0.8, 3.0). Lifetime substance use was investigated in secondary analyses. The high prevalence
of smoking in prison suggests that policies regarding smoking need careful review. Furthermore, the ﬁndings under-
score the importance of timely, scalable, and available treatments for alcohol and illegal drug use by people involved
with the criminal justice system.
alcohol; illicit drugs; injection drug use; nicotine; prevalence; prison; substance use
Abbreviations: CI, conﬁdence interval; LMIC, low- andmiddle-income country.
INTRODUCTION
Prison populations in low- and middle-income countries
(LMICs) have been increasing over the past few decades (1).
The increase has been especially pronounced in the Americas
and in Oceania. Since the year 2000, prison populations
increased by 60% in Oceania, by 80% in Central America, and
by 145% in South America (1, 2). Little is known about major
causes of morbidity in people involved with the criminal justice
system in LMICs, and prison health services rely on evidence
from high-income countries. In such settings, a major health
problem is substance use disorders (3, 4). These disorders
increase the risk of a range of adverse outcomes, including
infectious diseases (5), other mental health problems (6), and
death (7, 8), and of reoffending on release (9). Although there is
high-quality evidence from the general population and prison po-
pulations (10) for treatment, there appear to be substantial unmet
treatment needs in people involved with the criminal justice sys-
tem (11). In Latin America, for example, only 1% to 20% of pris-
ons have been reported to have specialized mental health services
(11). Bans and treatments in prisons may have continuing effects
after release, in contrast to approaches only focusing on forced
abstinence in the controlled prison environment (10, 12).
Imprisonment in LMICs is characterized by low budgets
that permit providing only basic services, and by overcrowding
and human rights violations (11, 13, 14). Human rights con-
cerns have been raised particularly for people with substance
use and other psychiatric disorders in prisons (15). In addition
to the lack of basic care, there has been little mental health
research in prison populations in LMICs (16); such research
could assist in providing an evidence base from which to
develop services. Based on limited research, it has been sug-
gested that there is a higher prevalence of mental disorders in
imprisoned LMIC populations (17); to our knowledge, how-
ever, substance use disorders have not been systematically
reviewed. This study aims to present a systematic review
and meta-analysis of substance use problems in imprisoned
people of LMICs while they are in custody and, secondar-
ily, to determine lifetime substance abuse rates.
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METHODS
This systematic review followed theMeta-analysis of Obser-
vational Studies in Epidemiology guidelines (18) and data are
reported according to the Preferred Reporting Items for System-
atic Reviews andMeta-Analyses (19).
Search strategy
A systematic search of the literature was conducted covering
the time from 1987, when the distinction betweenanalytical
classiﬁcation of countries in low-, middle-, and high-income
economies was introduced by the World Bank as a develop-
ment indicator (www.worldbank.org), until March 2017.
The search included 1) online databases (i.e., CAB Abstracts;
Embase; Global Health; MEDLINE; PsycINFO; Applied
Social Sciences Index and Abstracts; Criminal Justice Data-
base; International Bibliography of the Social Sciences; PAIS
Index; Social Services Abstracts; LILACS; and Scopus); 2)
key journals (e.g., Addiction; Addictive Behaviors), 3) refer-
ence lists of identiﬁed papers and relevant systematic reviews;
and 4) ProQuest Dissertations & Theses Global, Open Grey,
and correspondence with authors. For the online database
searches, we used a combined strategy of free-text strings
and subject headings related to substance use, prison set-
tings, and prevalence studies (detailed search terms and
strings are shown in Web Appendix 1, available at https://
academic.oup.com/aje; the results for each online database
are shown in Web Table 1, and those for the grey literature
are listed in Web Table 2). Non-English articles were
translated.
Inclusion and exclusion criteria
We identiﬁed studies in which prevalence rates were re-
ported of substance use in the general prison population. The
following inclusion criteria were applied: 1) Data were col-
lected from unselected general prison populations; 2) the
prevalence rates of the use of nicotine, alcohol, illicit drugs,
cannabis, cocaine, opiates, and/or injection drugs were estab-
lished with questionnaires or as part of a research interview;
3) the sampling was representative for the prison population
or the population of a facility; and 4) the study was con-
ducted in an LMIC at the time of data collection.
The following exclusion criteria were applied: 1) studies in
which a particular age group was selected, such as adolescents
or a particular offender type; 2) publications reporting data from
the same samples as other publications (themost comprehensive
publication was retained); 3) convenience sampling; 4) studies
only reporting the prevalence of substance use, applying the dis-
order criteria (and not the prevalence of substance use without
necessarily fulﬁlling disorder criteria); and 5) studies reporting
data collected before 1987 (Web Figure 1).
Data extraction
Two reviewers (G.B., C.G.) independently extracted the data
from the included studies. The following data were extracted:
sex, mean age, year and country of data collection, sample size,
nonresponse rate, type of substance use, and number of people
with any speciﬁc type of substance use. The periods covered by
the reported prevalence estimates were extracted and coded as
during imprisonment (i.e., point prevalence, including≤1 year)
and before imprisonment (including 1 year before imprison-
ment up to lifetime). When data were missing or clariﬁcation
was needed, authors of primary studies were contacted. We
included people on remand (i.e., in jails, pretrial, and detainees)
and sentenced individuals. If the prevalence of heroin use was
reported in addition to the prevalence of other opiate use, rates
were added to infer the overall prevalence of opiate use. If the
prevalence of heroin use was reported as being part of the group
of opiate use or vice versa, the higher rate was extracted as the
overall prevalence of opiate use. For countries in Europe,
Asia, and Africa that did not report opiate use but did report
injection drug use, the latter was taken as a proxy for opiate use
as well.
Statistical analysis
If publications reported prevalence estimates separately for
men and women or for samples from different countries, they
were included in the statistical analyses as different samples.
As a consequence, the number of samples is higher than the
number of studies. Studies in which less than 10% of partici-
pants were of 1 sexwere considered representative for the other
sex. Separate meta-analyses were conducted for the rates before
and during imprisonment. To account for high heterogeneity
between the samples, we used random-effects models to balance
the weighting of studies for data syntheses (20). To allow com-
parison between random- and ﬁxed-effects models, ﬁxed-
effects meta-analyses also were calculated. Wilson’s method
was used to calculate 95% conﬁdence intervals for prevalence
estimates (21). Heterogeneity among studies was estimated
based on Cochran Q test and reported using the I2 statistic
and 95% conﬁdence interval. I2 > 75% indicated high hetero-
geneity (22).
Random-effects meta-regressions were conducted to assess
the effects of prespeciﬁed sample characteristics on the prev-
alence of substance use. In additional secondary analyses, we
included rates of substance use before imprisonment as vari-
ables in the regression analyses when assessing the heterogeneity
of substance use during imprisonment. Ratios of pooled random-
effects prevalence estimates before and during imprisonment
were calculated. Ratios (and 95% conﬁdence intervals) of the
prevalence in the prison population to the prevalence of the
sex-matched general population were calculated for nicotine
use because data from the general population were available for
most countries. Statistical analyses were conducted with Stata,
version 13 (StataCorp LP, College Station, Texas), using the
commands metaprop for meta-analyses, metareg for meta-
regressions, and metan for the prevalence ratios.
RESULTS
In 83 studies (n= 94 samples), prevalence rates were reported
for substance use by 89,667 individuals whowere imprisoned in
32 LMICs within 6 regions as deﬁned by the World Health
Epidemiol Rev. 2018;40:70–81
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Organization: Africa, Americas, EasternMediterranean, Europe,
Southeast Asia, andWestern Paciﬁc (Web Figure 2).
Nicotine use
We identiﬁed 24 samples from 17 LMICs reporting preva-
lence data on nicotine use during imprisonment (23–43). The
prevalence of nicotine use during imprisonment ranged from
5% in Ethiopia to 87% in Lithuania. The heterogeneity among
the studies was very high (I2 = 99%; P < 0.01). The prevalence
was 56% (95% conﬁdence interval (CI): 45, 66), according
to pooled random-effects models, among people imprisoned
in LMICs (Figure 1). Prevalence of nicotine use was higher
in the Americas (58%; β = 0.327; P = 0.03) and in Europe
Overall (I² = 99%, P < 0.001)
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Figure 1. Prevalence and random-effects meta-analyses of nicotine use during imprisonment in low- and middle-income countries by regions as
deﬁned by the World Health Organization, 1987–2017. The dashed line indicates the overall pooled random-effects prevalence. CI, conﬁdence
interval; PGN, PapuaNewGuinea.
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(75%; β = 0.483; P = 0.001) as compared with Africa, ac-
cording to meta-regression (Web Table 3).
Alcohol use
Alcohol use during imprisonment was reported in 19 samples
from 15 LMICs (23, 24, 29, 30, 32–34, 40, 41, 44–51). Preva-
lence ranged from 1% to 76%; between-study heterogeneity was
very high (I2 = 99%; P < 0.01). The random-effects pooled
prevalencewas 16% (95%CI: 9, 25) (Figure 2).Meta-regression
analyses did not show any associations between predetermined
study characteristics and alcohol use during imprisonment (Web
Table 4).
Illicit drug use during imprisonment
There were 26 samples from 14 LMICs reporting prevalence
estimates for any illicit drug use during imprisonment (30, 31,
34, 35, 38, 45, 47–49, 51–65). These estimates ranged from 0%
for imprisonedwomen in Lithuania to 78% for male prisoners in
Kyrgyzstan (I2 = 99%; P < 0.01) (Figure 3). Random-effects
pooled prevalence was 25% (95% CI: 17, 33) (Figure 3). No
Overall (I² = 99%, P < 0.001)
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Figure 2. Prevalence and random-effects meta-analyses of alcohol use during imprisonment in low- and middle-income countries by regions as
deﬁned by the World Health Organization, 1987–2017. The dashed line indicates the overall pooled random-effects prevalence. CI, conﬁdence
interval; PGN, PapuaNewGuinea.
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signiﬁcant associations between study characteristics were
found on meta-regression analysis (Web Table 5).
Cannabis use. Prevalence estimates of cannabis use dur-
ing imprisonment were reported for 30 samples in 16 LMICs
(23, 24, 27, 31, 32, 34, 40, 41, 43, 44, 46, 47, 50, 51, 53, 56–
58, 60–66); these varied from 1% to 55% (Web Figure 3), with
high heterogeneity (I2 = 99%; P < 0.01). Pooled prevalence
on random-effects meta-analysis was 17% (95% CI: 12, 23)
for cannabis use during imprisonment in LMICs. In theAmericas,
cannabis use was more frequent (25%; β = 0.145; P = 0.041)
than in Africa (Web Table 6).
Other drugs. Prevalence estimates of cocaine use during
imprisonment were reported for 20 samples in 8 LMICs (23,
27, 31, 32, 34, 41, 44, 46–48, 51, 53, 56, 60–64). Prevalence
estimates for cocaine use during imprisonment ranged from
0% to 29% (Web Figure 4). The heterogeneity between the
studies was high (I2 = 99.2%; P < 0.001). According to pooled
rates, the prevalence of cocaine use during imprisonment in
Overall (I² = 99%, P < 0.001)
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Figure 3. Prevalence and random-effects meta-analyses of illicit drug use during imprisonment in low- and middle-income countries by regions
as deﬁned by the World Health Organization, 1987–2017. The dashed line indicates the overall pooled random-effects prevalence. B&H, Bosnia
and Herzegovina; CI, conﬁdence interval.
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LMICs was 5% (95% CI: 2, 8). On meta-regression, no study
characteristics were associated with the prevalence of cocaine
use during imprisonment (Web Table 7).
Prevalence estimates of opiate use during imprisonment
were reported for 26 samples in 14 LMICs (23, 32, 34, 35, 41,
43, 44, 47, 50–52, 58–60, 62–65, 67–71); these rates varied
from 0% to 80% (Web Figure 5), with a pooled prevalence
of 6% (95% CI: 3, 11). No associations were found on meta-
regression (Web Table 8).
Injection drug use during imprisonment. Prevalence esti-
mates for injection drug use during imprisonment were reported
for 28 samples from 16 LMICs (27, 32, 35, 41, 45–48, 52, 54,
57–59, 64, 68–76); these rates varied from 0% to 26% (Fig-
ure 4). The pooled random-effects prevalence was 1.7% (95%
CI: 0.6, 3.1). The rate of injection drug use in European LMICs
was higher than in Africa, according to meta-regression analy-
ses (6.5%; β = 0.087; P = 0.027) (Web Table 9).
Other analyses
Prevalence rates of substance use before imprisonment are re-
ported in theWebAppendices 2–8 and in theWeb Figures 6–12
(24–27, 29, 32–35, 38, 40–42, 44–52, 54, 55, 57–106). Pooled
random-effects estimates were 70% for nicotine use (Web
Appendix 2 and Web Figure 6), 71% for alcohol use (Web
Appendix 3 and Web Figure 7), 48% for illicit drug use
(Web Appendix 4 and Web Figure 8), 37% for cannabis
use (Web Appendix 5 andWeb Figure 9), 23% for cocaine use
(Web Appendix 6 and Web Figure 10), 10% for opiate use
(Web Appendix 7 andWeb Figure 11), and 10% for injection
drug use (Web Appendix 8 and Web Figure 12). There was
clear geographical heterogeneity for nicotine use, alcohol use,
cocaine use, opiate use, and injection drug use before imprison-
ment (Web Tables 3–9).Web Table 10 lists all included studies
reporting the prevalence of substance use in prison populations
during or before imprisonment.
We assessed whether substance use before imprisonment
explained part of the heterogeneity of substance use during
imprisonment. For nicotine, alcohol, any illicit drug use, and
injection drug use, the prevalence before imprisonment was
not associated with heterogeneity. However, for cannabis
(P < 0.001), cocaine (P < 0.001), and opiate use (P < 0.001), the
prevalence before imprisonment was signiﬁcantly associated
with the prevalence during imprisonment, according to univar-
iate analyses (Web Tables 3–9). According to multivariate
meta-regression, sex (β = 0.198; P = 0.050) and imprison-
ment in Europe (β = 0.236; P = 0.009) retained statistical sig-
niﬁcance for the prevalence of nicotine use before imprisonment
(Web Table 3). Only cannabis use before imprisonment (β =
0.00018; P < 0.001) remained signiﬁcant for cannabis use
during imprisonment (Web Table 6). Regional heterogene-
ity for cocaine use before imprisonment was supported by
multivariate regression analysis, with higher prevalence in
the Americas (β = 0.389; P < 0.001) and in Europe (β = 0.104;
P = 0.031) (Web Table 7). For the prevalence of opiate use
before imprisonment, the prevalence in the Eastern Mediterra-
nean region (β = 0.135; P < 0.046) and the nonresponse rate
(β = 0.0022;P = 0.018) were signiﬁcant inmultivariate analyses
(Web Table 8). Ratios of pooled random-effects prevalence rates
before compared with during imprisonment were 1.3 (95% CI:
1.2, 1.3) for nicotine use; 4.4 (95% CI: 4.3, 4.6) for alcohol use;
2.0 (95% CI: 1.9, 2.0) for any illicit drug use; 2.2 (95% CI: 2.1,
2.3) for cannabis use; 4.9 (95% CI: 4.6, 5.2) for cocaine use; 1.7
(95%CI: 1.6, 1.8) for use of opiates; and 60 (95%CI: 55, 66) for
injection drug use. Ratios were consistently higher than 1, indic-
ating higher rates for substance use before than during imprison-
ment. Fixed-effects models for all analyses are presented inWeb
Table 11.
We estimated prevalence ratios for nicotine use, which were
prevalence rates among prison populations compared with sex-
matched estimates in the general population from the countries
where those prisonswere located. For nicotine, prevalence ratios
were all higher than 1 and ranged from 1.2 (95% CI: 0.9, 1.7) in
Ethiopia to 11.2 (95%CI: 10.4, 12.1) inMexico (Figure 5).
DISCUSSION
Main results
We have provided estimates of nicotine, alcohol, and illicit
drug use during imprisonment from a systematic review and
meta-analysis of 94 samples in 83 studies and nearly 90,000
people imprisoned in LMICs. There were 3 main ﬁndings.
First, the pooled random-effects prevalence of nicotine use
during imprisonment was 56%; the prevalence ratios of all the
included primary studies were higher than those of the general
populations. Second, a pooled prevalence of 16% was calcu-
lated for alcohol use during imprisonment, with wide varia-
tions in geographical prevalence. Third, it was estimated that
approximately one-quarter of the imprisoned people (pooled
prevalence, 25%, 95% CI: 17, 33) used illicit drugs during
imprisonment, and injection drug use during imprisonment
was estimated at 1.7% (95% CI: 0.6, 3.1).
Strength and limitations
To our knowledge, this is the ﬁrst systematic review of sub-
stance use problems in prison populations of LMICs worldwide.
We provide a sufﬁcient body of evidence from data synthesis
and have conducted meta-regression analyses examining sources
of heterogeneity. The pooled prevalence estimates have to be
interpreted with caution because of the high between-study
heterogeneity of the data, which would be expected, consid-
ering the differences in criminal justice systems and prisons
around the world. As a consequence, in addition to a random-
effects prevalence that assumes heterogeneity, we have provided
prevalence ranges and ﬁxed-effects models. The latter weigh
studies more by sample size and may be informative when
small study effects are considered strong. An additional limita-
tion of this study is the variability of the policy contexts with
respect to (partial) smoking bans and the implementation of
drug and alcohol bans.
Implications
In contrast to the other substances reviewed here, nicotine
use is legal in prisons in LMICs, to our knowledge. A principal
implication of this review is the need to review smoking policies
inside prisons in LMICs. Policy initiatives in this regard
are relatively new in high-income countries, where tobacco
Epidemiol Rev. 2018;40:70–81
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control generally has been more effective (107). Several high-
income countries have introduced smoking bans in prisons and
jails (108–111), which should reduce morbidity and death
among people involved in the criminal justice system (108).
Smoking bans during imprisonment combined with psycholog-
ical interventions before release can be successful in prolonging
abstinence from smoking after release (10). In the current
meta-analysis, we report more than half of the people impri-
soned in LMICs smoked during imprisonment, and thus, the
potential for addressing this is considerable. We also have
shown that these rates of nicotine use are substantially high-
er than in the general population of the speciﬁc countries of
the primary studies included in the review. Therefore, pol-
icies to ban smoking in prisons and treatments to reduce
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Figure 4. Prevalence and random-effects meta-analyses of injection drug use during imprisonment in low- and middle-income countries by re-
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nicotine addiction should be considered in LMICs, especially
in the Americas and in Europe, where the rates are particu-
larly high.
A second implication is the importance of ensuring that alco-
hol treatments are available in prisons in LMICs. There has been
considerable interest in addressing drug use, particularly as it is
associated with infectious diseases, but in this review, we found
that approximately 1 in 6 imprisoned people consumes alcohol
inside prison. Many of these individuals may not have alcohol
use disorders, but many do and will continue to on release.
Because alcohol is usually banned in prisons and difﬁcult to
smuggle, it is often produced inside prisons and, consequently,
tends to be of low quality and high toxicity (33, 112). Prison ser-
vices need to have available appropriate alcohol detoxiﬁcation
treatments on entry and to consider other interventions, includ-
ing group therapies and other psychosocial treatments that are
scalable (113). In addition, the heterogeneity of prevalence esti-
mates for alcohol use during imprisonment indicates the need
for local surveys to best inform service development. Such local
surveys may not be feasible owing to ﬁnancial pressures in
some countries; therefore, the estimates presented here could
be of assistance.
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A third implication is that the ﬁndings underscore the impor-
tance of addressing illicit drug use during imprisonment. High-
income countries have high rates and persistence of illicit drug
use during imprisonment, especially heroin use (114).We found
that approximately one-quarter of the prison population uses
illicit drugs during imprisonment. There is good evidence for the
effectiveness of opioid-substitution treatment in prison popula-
tions (115). However, apart from initiatives in a few countries
(116), treatment interventions are mostly unavailable in LMICs.
In addition, we report important regional differences in the prev-
alence of cannabis and possibly of opiate and cocaine use. This
would suggest that rather than 1 treatment model for all coun-
tries, interventionsmay need to be tailored at regional or national
levels for speciﬁc types of drug use problems.
Injection drug use is a risk factor for spreading HIV in prisons
in LMICs (117, 118). There remains a paucity of data available
from LMICs (117), with data from 32 countries and consider-
able heterogeneity in the ﬁndings. More research on the chang-
ing dynamics of injection drug use in LMICs is required.
Individual prevalence rates of speciﬁc types of illicit drugs
used before imprisonment, including cannabis, opiates, and
cocaine, explained part of the heterogeneity in illicit drug use
prevalence during imprisonment. We also found that prevalence
rates of substance use before imprisonment were consistently
higher than those during imprisonment for all substances. This
difference was more pronounced for alcohol than for illicit
drugs, suggesting that prison systems more effectively limit
alcohol than illicit drugs. Overall, this suggests that people
import their substance use problems into prison and further un-
derscores the need for intervention programs to be integrated
between the community and prison.
Conclusion
We report estimates of smoking, alcohol, and illicit drug use
during imprisonment in LMICs. Approximately 1 in 2 prison-
ers smokes, 1 in 6 drinks alcohol, and 1 in 4 uses illicit drugs.
From a public health perspective, these high rates represent an
opportunity for intervention, particularly because interventions
that are effective in other settings can be transferred to prisons.
Smoking bans in prisons, and scalable and available detoxiﬁca-
tion and addiction services have the potential to address the
large burdens of smoking and substance use in LMICs.
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